Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
This 16-week, real-world retrospective cohort study of a behavioral weight management program evaluated the efficacy of a lower dose of compounded semaglutide on weight loss.
Methods
Weight loss was compared among Noom Weight (NW) users, Noom Microdose GLP-1 Rx Program (NMGP) users prescribed a low dose of compounded semaglutide (up to 0.6mg/weekly), and Noom GLP-1 Rx Program (NGP) users prescribed a dose up to 1.2mg/weekly of compounded semaglutide via multiple-group latent growth curve models for the full sample and propensity score matched cohort. Users were matched on demographic characteristics, Area Deprivation Index, baseline Body Mass Index, and urbanicity.
Results
In the full sample, participants (N = 29,788) were mostly middle-aged, urban-dwelling females. At 16 weeks, NW users lost 2.6%, NMGP users lost 8.3%, and NGP users lost 8.6% of their baseline weight (all comparisons p ≤ .001). In the matched cohort (N = 3,657; n= 1,219 per group), participant characteristics were similar. At 16 weeks, NW users lost 2.6%, NMGP users lost 8.3%, and NGP users lost 9.1% of their initial weight (all comparisons p < .001).
Conclusions
This large, retrospective cohort reports lower doses of compounded semaglutide alongside a behavioral companion achieve 91% of the weight loss of a higher dose of compounded semaglutide in the first 16 weeks.
